For the quarter ending 2026-03-31, CHRS has $266,022K in assets. $187,399K in debts. $115,238K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 115,238 | 88,879 | 103,352 | 216,893 |
| Investments in marketable securities | 51,810 | 83,246 | 88,311 | 20,744 |
| Trade receivables, net | 22,064 | 17,815 | 9,245 | 5,109 |
| Tsa receivables, net | 446 | 603 | 241,251 | 114,530 |
| Inventory | 4,825 | 3,172 | 2,048 | 4,513 |
| Prepaid manufacturing | 2,273 | 6,758 | 8,048 | 6,700 |
| Other prepaids and current assets | 9,379 | 6,233 | 8,700 | 11,716 |
| Total current assets | 206,035 | 206,706 | 460,955 | 380,205 |
| Property and equipment, net | 1,094 | 1,345 | 1,633 | 1,907 |
| Inventory, non-current | 9,688 | - | - | - |
| Intangible assets, net | 45,614 | 46,239 | 49,484 | 52,312 |
| Other assets, non-current | 3,591 | 4,053 | 4,447 | 5,040 |
| Total assets | 266,022 | 258,343 | 516,519 | 439,464 |
| Accounts payable | 11,479 | 9,915 | 24,893 | 37,622 |
| Accrued rebates, fees and reserves | 28,766 | 30,397 | 67,010 | 96,814 |
| Tsa payables and accrued liabilities | 61,605 | 65,065 | 253,908 | 103,999 |
| Accrued compensation | 15,280 | 14,579 | 13,385 | 11,015 |
| Accrued and other current liabilities | 15,202 | 20,430 | 13,101 | 14,179 |
| Total current liabilities | 132,332 | 140,386 | 372,297 | 263,629 |
| Term loan, non-current | 37,147 | 37,051 | 36,957 | 36,867 |
| Lease liabilities, non-current | 954 | 1,457 | 1,946 | 2,406 |
| Other liabilities, non-current | 16,966 | 18,435 | 17,545 | 16,735 |
| Total liabilities | 187,399 | 197,329 | 428,745 | 319,637 |
| Common stock (0.0001 par value shares authorized 300,000,000 shares issued and outstanding 154,217,609 and 121,154,925 at march 31, 2026 and december 31, 2025, respectively) | 15 | 12 | 12 | 12 |
| Additional paid-in capital | 1,500,172 | 1,444,166 | 1,433,291 | 1,429,885 |
| Accumulated other comprehensive loss | -268 | -195 | -203 | -275 |
| Accumulated deficit | -1,421,296 | -1,382,969 | -1,345,326 | -1,309,795 |
| Total stockholders' equity | 78,623 | 61,014 | 87,774 | 119,827 |
| Total liabilities and stockholders' equity | 266,022 | 258,343 | 516,519 | 439,464 |
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)